This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Hologic (HOLX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (HOLX) Outperforming Other Medical Stocks This Year?
3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Instruments industry. NTUS, IDXX and HOLX are well positioned to gain.
AmerisourceBergen (ABC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AmerisourceBergen (ABC) is optimistic about maintaining a robust segmental performance amid the pandemic-led business disruptions.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction for solid product portfolio and improving margins. However, forex is a woe
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
Cardinal Health (CAH) Hits New 52-week High: What's Driving It?
by Zacks Equity Research
Cardinal Health (CAH) is witnessing an uptrend in its stock price, prompted by robust performance in both Pharmaceutical and Medical segments during the fiscal second quarter.
Why You Should Retain Varian (VAR) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on the Varian (VAR) stock, courtesy of its solid prospects.
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
MedTech to Gain From Economic Stimulus Bill: 3 Stocks to Buy
by Trina Mukherjee
Grab these three top stocks - ABT, HOLX and BIO - that continue to show tremendous promise and stand to benefit from the historic stimulus package.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $71.98, marking a -1.03% move from the previous day.
NEOGEN's (NEOG) Earnings Miss Estimates in Q3, Margins Up
by Zacks Equity Research
NEOGEN's (NEOG) third-quarter fiscal 2021 revenues increase 16.9% year over year, driven by strong segmental growth and robust international business.
Why You Should Add DENTSPLY SIRONA (XRAY) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in the DENTSPLY SIRONA (XRAY) stock, thanks to solid prospects.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD
by Zacks Equity Research
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients
by Zacks Equity Research
PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.
Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19
by Zacks Equity Research
Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.
Cooper Companies' (COO) Unit Assigns Vuzix M400 Smart Glasses
by Zacks Equity Research
Cooper Companies' (COO) unit assigns smart glasses to boost productivity in operations.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes
by Zacks Equity Research
IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Hologic (HOLX) on its strong molecular diagnostic growth and robust international performance.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Delay in FDA approval for latest COVID test hasn't altered growth or value at 3X sales